Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers - a pharmacovigilance study using the FDA adverse event reporting system
Favorite
Share
More Options
15

Open in WPS to view all 15 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
